Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial

被引：0
|
作者：
Vaduganathan, M. [1 ]
Sattar, N. [2 ]
Fitchett, D. [3 ]
Ofstad, A. [4 ]
Brueckmann, M. [5 ,6 ]
George, J. T. [5 ]
Verma, S. [3 ]
Mattheus, M. [7 ]
Wanner, C. [8 ]
Inzucchi, S. E. [9 ]
Zinman, B. [10 ]
Butler, J. [11 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Univ Glasgow, Glasgow, Lanark, Scotland
[3] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada
[4] Boehringer Ingelheim KS, Asker, Norway
[5] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[6] Heidelberg Univ, Mannheim, Germany
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[8] Univ Hosp Wurzburg, Wurzburg, Germany
[9] Yale Univ, Sch Med, Yale New Haven Hosp, New Haven, CT USA
[10] Univ Toronto, Mt Sinai Hosp, Toronto, ON, Canada
[11] Univ Mississippi, Jackson, MS 39216 USA
来源：
DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
572
引用
收藏
页码：S275 / S275
页数：1
相关论文
共 50 条
  • [41] Composite retinopathy outcome in patients treated with empagliflozin versus placebo in the EMPA-REG OUTCOME trial
    Inzucchi, S. E.
    Wanner, C.
    Hehnke, U.
    Lee, J.
    Kaspers, S.
    Clark, D.
    George, J. T.
    Zinman, B.
    DIABETOLOGIA, 2018, 61 : S300 - S300
  • [42] Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial
    Verma, Subodh
    Leiter, Lawrence A.
    Zinman, Bernard
    Sharma, Abhinav
    Mattheus, Michaela
    Fitchett, David
    George, Jyothis
    Ofstad, Anne Pernille
    Kosiborod, Mikhail N.
    Wanner, Christoph
    Inzucchi, Silvio E.
    ESC HEART FAILURE, 2021, 8 (04): : 2603 - 2607
  • [43] Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease: Survival Estimates From the EMPA-REG OUTCOME Trial
    Claggett, Brian
    Lachin, John M.
    Hantel, Stefan
    Fitchett, David
    Inzucchi, Silvio E.
    Woerle, Hans J.
    George, Jyothis T.
    Zinman, Bernard
    CIRCULATION, 2018, 138 (15) : 1599 - 1601
  • [44] Empagliflozin and cardiorenal outcomes in patients with non-proteinuric kidney disease in the EMPA-REG OUTCOME trial
    Wanner, C.
    Zinman, B.
    George, J. T.
    Mattheus, M.
    von Eynatten, M.
    Inzucchi, S. E.
    Hauske, S. J.
    DIABETOLOGIA, 2019, 62 : S5 - S5
  • [45] Effects of empagliflozin on cardiorenal outcomes in patients with type 2 diabetes and proteinuric diabetic kidney disease: insights from EMPA-REG OUTCOME
    Wanner, Christoph
    Zinman, Bernard
    von Eynatten, Maximilian
    Koitka-Weber, Audrey
    Zwiener, Isabella
    Hauske, Sibylle J.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35
  • [46] Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial
    Ferreira, Joao Pedro
    Inzucchi, Silvio E.
    Mattheus, Michaela
    Meinicke, Thomas
    Steubl, Dominik
    Wanner, Christoph
    Zinman, Bernard
    DIABETES OBESITY & METABOLISM, 2022, 24 (01): : 135 - 141
  • [47] Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients With Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME Trial
    Verma, Subodh
    Mazer, C. D.
    Fitchett, David
    Inzucchi, Silvio E.
    George, Jyothis T.
    Pfarr, Egon
    Woerle, Hans J.
    Zinman, Bernard
    CIRCULATION, 2017, 136 (24) : E456 - E456
  • [48] EMPA-REG OUTCOME: cardiovascular outcome trials in diabetes come of age
    Krentz, Andrew J.
    CARDIOVASCULAR ENDOCRINOLOGY, 2015, 4 (04): : 115 - 116
  • [49] Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial
    Pellicori, Pierpaolo
    Fitchett, David
    Kosiborod, Mikhail N.
    Ofstad, Anne P.
    Seman, Leo
    Zinman, Bernard
    Zwiener, Isabella
    Wanner, Christoph
    George, Jyothis
    Inzucchi, Silvio E.
    Testani, Jeffrey M.
    Cleland, John G. F.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (07) : 1085 - 1093
  • [50] Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial
    Hadjadj, Samy
    Cooper, Mark E.
    Steubl, Dominik
    Petrini, Michaela
    Hantel, Stefan
    Mattheus, Michaela
    Wanner, Christoph
    Thomas, Merlin C.
    KIDNEY MEDICINE, 2024, 6 (03)
12345